Literature DB >> 22426030

Using virally expressed melanoma cDNA libraries to identify tumor-associated antigens that cure melanoma.

Jose Pulido1, Timothy Kottke, Jill Thompson, Feorillo Galivo, Phonphimon Wongthida, Rosa Maria Diaz, Diana Rommelfanger, Elizabeth Ilett, Larry Pease, Hardev Pandha, Kevin Harrington, Peter Selby, Alan Melcher, Richard Vile.   

Abstract

Multiple intravenous injections of a cDNA library, derived from human melanoma cell lines and expressed using the highly immunogenic vector vesicular stomatitis virus (VSV), cured mice with established melanoma tumors. Successful tumor eradication was associated with the ability of mouse lymphoid cells to mount a tumor-specific CD4(+) interleukin (IL)-17 recall response in vitro. We used this characteristic IL-17 response to screen the VSV-cDNA library and identified three different VSV-cDNA virus clones that, when used in combination but not alone, achieved the same efficacy against tumors as the complete parental virus library. VSV-expressed cDNA libraries can therefore be used to identify tumor rejection antigens that can cooperate to induce anti-tumor responses. This technology should be applicable to antigen discovery for other cancers, as well as for other diseases in which immune reactivity against more than one target antigen contributes to disease pathology.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22426030      PMCID: PMC3891505          DOI: 10.1038/nbt.2157

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


  42 in total

1.  Downstream region of the human tyrosinase-related protein gene enhances its promoter activity.

Authors:  K Shibata; K Takeda; Y Tomita; H Tagami; S Shibahara
Journal:  Biochem Biophys Res Commun       Date:  1992-04-30       Impact factor: 3.575

2.  Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease.

Authors:  Marilyn Fernandez; Mercedes Porosnicu; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

Review 3.  Treating cancer with genetically engineered T cells.

Authors:  Tristen S Park; Steven A Rosenberg; Richard A Morgan
Journal:  Trends Biotechnol       Date:  2011-06-12       Impact factor: 19.536

Review 4.  Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo.

Authors:  Hiroshi Uchi; Rodica Stan; Mary Jo Turk; Manuel E Engelhorn; Gabrielle A Rizzuto; Stacie M Goldberg; Jedd D Wolchok; Alan N Houghton
Journal:  Adv Immunol       Date:  2006       Impact factor: 3.543

5.  VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling.

Authors:  Phonphimon Wongthida; Rosa M Diaz; Feorillo Galivo; Timothy Kottke; Jill Thompson; Alan Melcher; Richard Vile
Journal:  Mol Ther       Date:  2010-10-19       Impact factor: 11.454

6.  Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.

Authors:  Thomas W Geisbert; Joan B Geisbert; Anders Leung; Kathleen M Daddario-DiCaprio; Lisa E Hensley; Allen Grolla; Heinz Feldmann
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

7.  Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy.

Authors:  Jian Qiao; Timothy Kottke; Candice Willmon; Feorillo Galivo; Phonphimon Wongthida; Rosa Maria Diaz; Jill Thompson; Pamela Ryno; Glen N Barber; John Chester; Peter Selby; Kevin Harrington; Alan Melcher; Richard G Vile
Journal:  Nat Med       Date:  2007-12-09       Impact factor: 53.440

8.  A simple method to cure established tumors by inflammatory killing of normal cells.

Authors:  Gregory A Daniels; Luis Sanchez-Perez; Rosa Maria Diaz; Timothy Kottke; Jill Thompson; Maoyi Lai; Michael Gough; Mahzuz Karim; Andrew Bushell; Heung Chong; Alan Melcher; Kevin Harrington; Richard G Vile
Journal:  Nat Biotechnol       Date:  2004-08-01       Impact factor: 54.908

9.  Induction of hsp70-mediated Th17 autoimmunity can be exploited as immunotherapy for metastatic prostate cancer.

Authors:  Timothy Kottke; Luis Sanchez-Perez; Rosa Maria Diaz; Jill Thompson; Heung Chong; Kevin Harrington; Stuart K Calderwood; Jose Pulido; Nick Georgopoulos; Peter Selby; Alan Melcher; Richard Vile
Journal:  Cancer Res       Date:  2007-12-15       Impact factor: 12.701

10.  Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Authors:  Willem W Overwijk; Marc R Theoret; Steven E Finkelstein; Deborah R Surman; Laurina A de Jong; Florry A Vyth-Dreese; Trees A Dellemijn; Paul A Antony; Paul J Spiess; Douglas C Palmer; David M Heimann; Christopher A Klebanoff; Zhiya Yu; Leroy N Hwang; Lionel Feigenbaum; Ada M Kruisbeek; Steven A Rosenberg; Nicholas P Restifo
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  60 in total

1.  Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment.

Authors:  Trudy Straetemans; Cor Berrevoets; Miriam Coccoris; Elike Treffers-Westerlaken; Rebecca Wijers; David K Cole; Valerie Dardalhon; Andrew K Sewell; Naomi Taylor; Jaap Verweij; Reno Debets
Journal:  Mol Ther       Date:  2014-11-03       Impact factor: 11.454

2.  Selecting antigens for cancer vaccines.

Authors:  Francesca Avogadri; Jedd D Wolchok
Journal:  Nat Biotechnol       Date:  2012-04-10       Impact factor: 54.908

3.  Immunotherapy exposes cancer stem cell resistance and a new synthetic lethality.

Authors:  Laszlo Radvanyi
Journal:  Mol Ther       Date:  2013-08       Impact factor: 11.454

4.  Panorama from the oncolytic virotherapy summit.

Authors:  Jonathan G Pol; Monique Marguerie; Rozanne Arulanandam; John C Bell; Brian D Lichty
Journal:  Mol Ther       Date:  2013-10       Impact factor: 11.454

5.  Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies.

Authors:  Masataka Suzuki
Journal:  Mol Ther       Date:  2017-03-18       Impact factor: 11.454

Review 6.  Oncolytic viruses and their application to cancer immunotherapy.

Authors:  E Antonio Chiocca; Samuel D Rabkin
Journal:  Cancer Immunol Res       Date:  2014-04       Impact factor: 11.151

7.  Recent advances in vesicular stomatitis virus-based oncolytic virotherapy: a 5-year update.

Authors:  Sébastien A Felt; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2017-12       Impact factor: 3.891

Review 8.  Trial watch: DNA-based vaccines for oncological indications.

Authors:  Stefano Pierini; Renzo Perales-Linares; Mireia Uribe-Herranz; Jonathan G Pol; Laurence Zitvogel; Guido Kroemer; Andrea Facciabene; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2017-11-20       Impact factor: 8.110

Review 9.  Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.

Authors:  Eric Hastie; Valery Z Grdzelishvili
Journal:  J Gen Virol       Date:  2012-10-10       Impact factor: 3.891

10.  Maraba virus as a potent oncolytic vaccine vector.

Authors:  Jonathan G Pol; Liang Zhang; Byram W Bridle; Kyle B Stephenson; Julien Rességuier; Stephen Hanson; Lan Chen; Natasha Kazdhan; Jonathan L Bramson; David F Stojdl; Yonghong Wan; Brian D Lichty
Journal:  Mol Ther       Date:  2013-10-25       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.